Semaglutide and Cardiovascular Risk: What SELECT Actually Showed
The SELECT trial found a 20% reduction in major cardiac events — independent of weight loss. Here's what that means, and what it doesn't.
GLP-1 receptor agonists started as diabetes drugs. Then they became weight-loss drugs. The SELECT trial is the moment they started to look like cardiovascular drugs — and that shift matters more than the headlines suggested.
What the trial measured
SELECT enrolled 17,604 adults with established cardiovascular disease and a BMI of 27 or higher, but without diabetes. Participants received either semaglutide 2.4mg weekly or placebo, and were followed for a mean of 39.8 months.
The primary endpoint was a composite of cardiovascular death, non-fatal heart attack, or non-fatal stroke.
Semaglutide reduced major adverse cardiovascular events by 20% versus placebo — a result that held across subgroups.
Why “independent of weight loss” is the interesting part
The intuitive story is simple: people lost weight, so their hearts did better. But the effect appeared earlier than the weight curve would predict, and held after statistical adjustment for weight change.
That points to mechanisms beyond appetite regulation — possibly direct effects on inflammation, endothelial function, or blood pressure. We don’t have the full picture yet, and honest interpretation means saying so.
What this does not mean
- It does not mean semaglutide is a primary-prevention drug for healthy people. SELECT studied people with existing cardiovascular disease.
- It does not mean the weight loss is irrelevant — only that it doesn’t explain the whole effect.
- It does not replace the foundational work: training, sleep, and nutrition still do the heavy lifting.
The takeaway
For people who already have cardiovascular disease and excess weight, SELECT strengthens the case for GLP-1 therapy as more than a metabolic tool. For everyone else, it’s a signal worth watching — not yet a prescription.
This is sample content created during site scaffolding. Replace with reviewed, fully-cited editorial before launch.